Share This Page
Drug Price Trends for NDC 62011-0229
✉ Email this page to a colleague
Average Pharmacy Cost for 62011-0229
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HM CAL ANTACID 750 MG CHEW TAB | 62011-0229-01 | 0.03250 | EACH | 2025-02-19 |
| HM CAL ANTACID 750 MG CHEW TAB | 62011-0229-01 | 0.03208 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62011-0229
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62011-0229
Introduction
NDC 62011-0229 corresponds to Ertapenem for Injection, marketed under the brand name Invanz by Merck & Co. This carbapenem antibiotic plays a critical role in treating severe bacterial infections, including intra-abdominal infections, skin and soft tissue infections, and bacterial pneumonia. Its therapeutic efficacy, limited competition, and evolving market dynamics underscore the importance of rigorous market analysis and accurate price projections for stakeholders ranging from pharmaceutical companies to healthcare providers and payers.
This report presents a comprehensive analysis of the current market landscape, explores influencing factors, and provides forward-looking price projections for NDC 62011-0229, considering global trends, competitive pressures, regulatory changes, and economic influences.
Market Landscape Overview
Current Market Position
Invanz (ertapenem) is a leading carbapenem antibiotic, with substantial adoption in hospital settings, especially for multidrug-resistant bacterial infections. Its once-daily dosing regimen confers advantages in clinical compliance and hospital formulary placement versus other carbapenems like meropenem or imipenem.
Despite its established presence, the antibiotic market faces specific challenges:
- Limited pipeline and generic maturation: Patent exclusivity has now ended in several jurisdictions, leading to increased generic competition.
- Growing antimicrobial stewardship: Promotes judicious use, which can restrict volume growth.
- Resistance trends: Rising carbapenem-resistant organisms may influence prescribing patterns and market size.
Competitive Dynamics
As of 2023, generic versions of ertapenem have entered the market in multiple regions, exerting downward pressure on pricing. Clinical alternatives like meropenem and doripenem provide competition, especially with broader spectrum activity, although ertapenem retains niche positioning owing to its efficacy against specific pathogens and pharmacokinetic benefits.
Key competitors include:
- Generic ertapenem formulations from multiple manufacturers.
- Alternative antibiotics with similar spectrum coverage, depending on resistance and susceptibility patterns.
Regulatory and Patent Status
Patent protections for Invanz expired or are nearing expiration globally, fostering generic entry. Regulatory pathways continue to evolve, with some countries streamlining approval processes for generics, accelerating price competition.
Market Drivers and Constraints
Market Drivers
- Increased prevalence of multidrug-resistant infections: Rising incidence of resistant Gram-negative organisms sustains demand for carbapenems.
- Hospital formulary adoption: Intravenous administration and dosing convenience favor Invanz in inpatient settings.
- Expanding indications: Off-label use and supportive indications may enhance utilization.
Constraints
- Antimicrobial stewardship initiatives and guidelines: Aim to curb empiric use, especially of broad-spectrum agents.
- Generic competition: Significantly decreased prices due to biosimilar and generic entries.
- Pricing pressures from payers and governments: Focused on cost containment in healthcare.
Price Analysis
Current Pricing Landscape
- Brand-name Invanz (NDC 62011-0229): Historically commanded premium pricing, reflecting brand recognition, clinical advantages, and limited generic competition until recent market entries.
- Generic equivalents: Now available at substantially lower prices, with some reports indicating reductions of 40-60% compared to branded versions.
Pricing Trends and Projections
Based on market data, current trends suggest:
- Declining average selling prices (ASPs): Over the last 12-24 months, ASPs for ertapenem have decreased notably across North America, Europe, and other regions due to increased generic availability.
- Regional variation: Price declines are more significant in regions with robust generic markets (e.g., Europe, North America). Developing markets may still see higher prices due to limited generic penetration.
Forecast assumptions:
- Short-term (1-2 years): Continued decline in ASPs, averaging a 20-30% reduction from current brand prices.
- Mid-term (3-5 years): Possible stabilization or slight increase if resistance patterns drive demand, but overall prices likely to remain suppressed due to generic competition.
- Long-term (>5 years): Market maturity may suppress prices further unless innovation, expanded indications, or exclusivity extensions occur.
Market Volume Projections
Volume projections depend on several factors:
- Global infection rates: Expected growth in multidrug-resistant infections.
- Hospital utilization rates: Influenced by new hospitals, protocol changes, and antimicrobial stewardship.
- Generic market penetration: Drives substitution from brand-name formulations.
Analysts project:
- Moderate growth in overall distribution volume, approximately 2-4% annually over the next 5 years.
- Potential for fluctuations in specific regions influenced by regulation, patent status, and clinical guidelines.
Economic Impact and Price Sensitivity
Price sensitivity remains high in the infectious disease market, especially with the proliferation of generics. Driven by payers' emphasis on cost-effectiveness, hospitals and healthcare systems prioritize lower-cost options unless clinical advantages justify premium prices.
Manufacturers may consider implementing strategic pricing to maintain market share, including:
- Tiered pricing strategies for different regions.
- Volume discounts for bulk hospital procurement.
- Innovative value-based pricing models linked to clinical outcomes.
Regulatory and Policy Influences
New antimicrobial stewardship policies, incentivized development programs, and potential government procurement initiatives could influence pricing and market size.
Increased scrutiny on antibiotic use may favor narrower-spectrum agents like ertapenem, potentially constraining volume but maintaining stable revenue streams through price strategies.
Key Investment and Commercial Strategies
- Focus on geographies with delayed generic entry: Potential for premium pricing temporarily.
- Developing combination regimens: Could expand indication spectrum.
- Monitoring resistance patterns: To anticipate shifts in demand and pricing.
Conclusions
The market for NDC 62011-0229 (ertapenem) is experiencing a transition from brand dominance to generic-driven price competition. Expect a continued downward pressure on prices, with potential stabilization in mature markets. The declining ASPs, coupled with steady demand driven by resistant infections, suggest a challenging but vital role for ertapenem in antimicrobial stewardship.
Stakeholders should adapt by deploying differentiated strategies, leveraging clinical value, and negotiating procurement terms favorably amidst evolving market conditions.
Key Takeaways
- Market penetration is shifting towards generics: Expect significant price declines, averaging 20-30% in the coming 1-2 years.
- Demand remains supported by increasing multidrug-resistant infections, but stewardship efforts may constrain volume growth.
- Regional variations influence pricing and volume, with developed markets seeing sharper generic competition.
- Long-term prospects depend heavily on resistance trends, regulatory changes, and innovation pipeline, which could modify current projections.
- Strategic positioning in terms of pricing, formulary acceptance, and clinical differentiation will be crucial for stakeholders aiming to optimize returns.
Frequently Asked Questions (FAQs)
1. How does generic entry impact the price of erapenem?
Generic entry leads to significant price erosion due to increased competition, often reducing prices by 40-60%, depending on regional market dynamics.
2. Are there emerging competitors to ertapenem?
While no direct new agents currently challenge ertapenem’s position, alternative antibiotics and combination therapies may influence demand and prescribing choices.
3. How will antimicrobial resistance trends influence the market?
Rising resistance can increase demand for potent carbapenems like ertapenem, but stewardship efforts to limit broad-spectrum use may counteract volume growth.
4. What regional differences should stakeholders consider?
Pricing pressures are more pronounced in North America and Europe due to earlier patent expirations and active generic markets. Emerging markets might still see higher prices due to limited generic availability.
5. Can value-based pricing strategies benefit manufacturers?
Yes. Demonstrating superior clinical outcomes or expanded indications can justify premium pricing, especially in settings where resistance issues drive more conservative prescribing.
References
[1] Market intelligence reports on carbapenem antibiotics.
[2] MDLinx, Antibiotic Market Trends, 2023.
[3] FDA and EMA patent status updates, 2023.
[4] Peer-reviewed articles on antimicrobial resistance trends, 2022–2023.
[5] Global healthcare procurement data, 2022–2023.
More… ↓
